The Company anticipates that an interim analysis of the complete 30-day follow-up data on the first half (50%) of patients enrolled in the trial will be completed in the first quarter of 2010. Further, the Company anticipates completing enrollment in and having top-line data available from this trial in the second half of 2010.
#2 -
ROTH CAPITAL PARTNERS TO HOLD 22ND ANNUAL OC GROWTH STOCK CONFERENCE - March 15-17, 2010
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.